Pediatric Cardiology and Congenital Heart Diseases, Centre for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Paediatr Drugs. 2022 Nov;24(6):603-655. doi: 10.1007/s40272-022-00514-1. Epub 2022 Sep 2.
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.
非甾体抗炎药(NSAIDs)在全球范围内广泛用于婴儿、儿童和青少年;然而,尽管有足够的证据表明 NSAIDs 对儿童和青少年有益,但婴儿的综合数据仍然缺乏。本综述总结了目前关于婴儿使用的各种 NSAIDs 的安全性和疗效的现有知识,其中包括布洛芬、右旋布洛芬、酮洛芬、氟比洛芬、萘普生、双氯芬酸、酮咯酸、吲哚美辛、尼氟酸、美洛昔康、塞来昔布、帕瑞昔布、罗非昔布、乙酰水杨酸和尼美舒利。NSAIDs 的疗效已在各种疾病中得到证实,如发热和疼痛。NSAIDs 也是儿科炎症性风湿病等抗炎治疗的主要支柱。关于大多数 NSAIDs 在婴儿中的安全性,可用数据有限。药物不良反应可能是肾、胃肠、血液学或免疫性的。由于 NSAIDs 是儿科人群中最常使用的药物之一,因此可以在正常临床常规中进行安全性和疗效研究,即使是在婴儿中。应使用可用的数据源(如电子病历)进行安全性和疗效分析。在更大的范围内,应使用特定于儿童的方法评估现有的数据源(如药物不良反应计划/网络、自发国家报告系统和电子病历),以检测与特定儿科年龄组或疾病实体相关的安全信号。为了提高 NSAIDs 在婴儿中的安全性,需要以最低的适合年龄或体重的剂量开始治疗。应定期评估治疗持续时间和药物使用量,并遵循制造商或专家委员会规定的最大剂量限制和其他建议。治疗非慢性疾病(如发热和急性(术后)疼痛)应尽可能缩短。患有慢性疾病的患者应定期监测 NSAIDs 的可能不良反应。